ArticleEFSA journal. European Food Safety Authority2017
Appropriateness to set a group health based guidance value for nivalenol and its modified forms.
Article in EFSA journal. European Food Safety Authority, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pooled it
- Human Biomonitoring of Mycotoxins in Blood, Plasma and Serum in Recent Years: A Review.Toxins · 2020Pooled it
- Modified Mycotoxins in Food: Current Evidence, Key Uncertainties, and Priorities for Risk Assessment.Comprehensive reviews in food science and food safety · 2026Review
- Article
- Mycotoxin contamination in moldy slices of bread is mostly limited to the immediate vicinity of the visible infestation.Food chemistry: X · 2024Article
- Frequent Dietary Multi-Mycotoxin Exposure in UK Children and Its Association with Dietary Intake.Toxins · 2024Article
- Contamination and Control of Mycotoxins in Grain and Oil Crops.Microorganisms · 2024Review
- Zearalenone-14-glucoside specifically promotes dysplasia of Gut-Associated Lymphoid Tissue: A natural product for constructing intestinal nodular lymphatic hyperplasia model.Journal of advanced research · 2023Article
- Review
- Combined Exposure to Multiple Mycotoxins: An Example of Using a Tiered Approach in a Mixture Risk Assessment.Toxins · 2022Article
- Mycotoxins' Toxicological Mechanisms Involving Humans, Livestock and Their Associated Health Concerns: A Review.Toxins · 2022Review
- Agronomic Factors Influencing the Scale ofJournal of fungi (Basel, Switzerland) · 2021Article
- Overall Exposure of European Adult Population to Mycotoxins by Statistically Modelled Biomonitoring Data.Toxins · 2021Article
- In Vitro Evaluation of the Individual and Combined Cytotoxic and Estrogenic Effects of Zearalenone, Its Reduced Metabolites, Alternariol, and Genistein.International journal of molecular sciences · 2021Article
- Article
- Mycotoxins-Biomonitoring and Human Exposure.Toxins · 2021Review
- Article
- Transformations of SelectedToxins · 2020Article
- Article
- Risk assessment methodologies in the field of contaminants, food contact materials, technological ingredients and nutritional risks.EFSA journal. European Food Safety Authority · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol since the previous opinion on nivalenol published in 2013, but as no new relevant data were identified the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 μg/kg body weight (bw) established on bases of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 μg/kg bw was established based on acute emetic events in mink. The only phase I metabolite of NIV identified is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc). DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals amounting up to about 50% of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it would rather overestimate than underestimate any risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.